MyFinsight
Home
Blog
About
Karyopharm Therapeutics Inc. (KPTI)
Karyopharm Therapeutics Inc. (KPTI)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Change in fair value of embedded...
Interest expense added to debt p...
Accrued expenses and other liabi...
Others
Negative Cash Flow Breakdown
Net loss
Purchases of investments
Accounts receivable, net
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-67,023
-22,392
-102,198
-93,841
Stock-based compensation expense
1,929
3,007
3,903
10,147
Depreciation
-3
12
19
277
Amortization of debt issuance costs and discounts
2,557
2,362
2,445
8,101
Interest expense added to debt principal
4,392
6,911
6,258
-
Net amortization of premiums and discounts on investments
90
-2
9
401
Loss (gain) on extinguishment of debt
-
-
-62,365
0
Change in fair value of embedded derivatives and common stock warrants
-32,035
16,481
-9,889
10,596
Accounts receivable, net
6,514
-2,821
-5,699
1,111
Inventory
395
-439
72
-773
Prepaid expenses and other assets
-1,119
-659
93
-4,219
Operating lease right-of-use assets
-149
-139
-132
-1,204
Accounts payable
3,381
276
-1,389
285
Accrued expenses and other liabilities
3,767
-257
1,441
17,622
Operating lease liabilities
-235
-226
-218
-220
Net cash used in operating activities
-24,931
-22,728
-11,828
-63,541
Purchases of investments
10,036
-
0
0
Purchases of property and equipment
-
-
0
0
Proceeds from maturities of investments
0
3,200
5,000
38,378
Net cash (used in) provided by investing activities
-10,036
3,200
5,000
38,378
Proceeds from convertible debt
-
-
15,000
-
Proceeds from senior secured term loan
-
-
12,250
0
Proceeds from issuance of common stock under open market sale agreement
0
20,233
-
-
Proceeds from issuance of common stock and warrants in private placement offering
0
30,000
8,750
-
Proceeds from the exercise of stock options and shares issued under the employee stock purchase plan
574
-
405
356
Payment of debt issuance costs
-
-
-
0
Payment of convertible debt
-
-
250
-
Payment of deferred royalty obligation
-
-
0
0
Payment of equity issuance costs
1,472
431
6,463
-
Net cash provided by financing activities
-898
49,802
29,692
356
Effect of exchange rates on cash, cash equivalents and restricted cash
-4
2
5
15
Net decrease in cash, cash equivalents and restricted cash
-35,869
30,276
22,869
-24,792
Cash, cash equivalents and restricted cash at beginning of period
91,167
60,891
39,075
39,075
Cash, cash equivalents and restricted cash at end of period
55,298
-
-
-
Cash and cash equivalents
54,980
-
-
-
Long-term restricted cash
318
-
-
-
Total cash, cash equivalents and restricted cash
55,298
91,167
60,891
38,022
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Net decrease in
cash, cash...
-$35,869K
Change in fair value of
embedded derivatives and...
-$32,035K
Interest expense added to
debt principal
$4,392K
Accrued expenses and
other liabilities
$3,767K
Accounts payable
$3,381K
Amortization of debt issuance
costs and discounts
$2,557K
Stock-based compensation
expense
$1,929K
Prepaid expenses and
other assets
-$1,119K
Operating lease
right-of-use assets
-$149K
Proceeds from the
exercise of stock options...
$574K
Net cash used in
operating activities
-$24,931K
Net cash (used in)
provided by investing...
-$10,036K
Net cash provided by
financing activities
-$898K
Effect of exchange
rates on cash, cash...
-$4K
Canceled cashflow
$49,329K
Canceled cashflow
$574K
Net loss
-$67,023K
Purchases of investments
$10,036K
Payment of equity
issuance costs
$1,472K
Accounts receivable, net
$6,514K
Inventory
$395K
Operating lease
liabilities
-$235K
Net amortization of
premiums and discounts on...
$90K
Depreciation
-$3K
Buy us a coffee